Error
  • The template for this display is not available. Please contact a Site administrator.

SGLT2WOEBanner

SGLT2 Inhibition: Questions and answers for an emerging therapy


To date, management of diabetes has focussed on enhanced insulin secretion or sensitivity to the hormone. An emerging strategy enhances renal elimination of glucose from the body by blocking the SGLT2 transporter. This UKidney Wall of Experts addresses questions related the SGLT2 inhibitors, an emerging treatment option.

What is the role of the kidney in glucose homeostasis?

Dr. Jordan Weinstein

What is the role of the kidney in glucose homeostasis?

This question covers the basics of glucose handling by the kidney
Press play

What is the role of the kidney in diabetes pathophysiology?

Dr. Jordan Weinstein

 

What is the role of the kidney in diabetes pathophysiology?

This question covers the role of diabetes in diabetes
Press play

What is the rationale for SGLT2 inhibition in diabetes?

Dr. Jordan Weinstein

 

What is the rationale for SGLT2 inhibition in diabetes?

This question covers the rationale of using SGLT2 inhibition to treat diabetes
Press play

What is the clinical impact of SGLT2 Inhibition?

Dr. Jordan Weinstein

 

What is the clinical impact of SGLT2 Inhibition?

This question reviews the emerging data when using SGLT2 inhibitors to treat diabetes.
Press play

What are the safety considerations of SGLT2 inhibition?

Dr. Jordan Weinstein

 

What are the safety considerations of SGLT2 inhibition?

This question reviews the emerging safety data available for SGLT2 inhibitors
Press play

What are the take-home messages on SGLT2 inhibition?

Dr. Jordan Weinstein

 

What are the take-home messages on SGLT2 inhibition?

This question reviews the take home messages of the kidney and diabetes and the emerging class of SGLT2 inhibitors
Press play

About this material

< br />

Dr. Jordan Weinstein is a nephrologist at St. Michael's Hospital and Assistant Professor of Medicine at the University of Toronto. This program is supported by an arm's length grant by Janssen Inc. The content and slides appearing in this feature was developed by Dr. Weinstein.

SGLT2 MOA Video

English

French